

Kornelis S M Van Der Geest

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8521129/publications.pdf>

Version: 2024-02-01

67
papers

1,531
citations

331259

21
h-index

360668

35
g-index

67
all docs

67
docs citations

67
times ranked

1460
citing authors

#	ARTICLE	IF	CITATIONS
1	Aging disturbs the balance between effector and regulatory CD4+ T cells. <i>Experimental Gerontology</i> , 2014, 60, 190-196.	1.2	115
2	Disturbed B Cell Homeostasis in Newly Diagnosed Giant Cell Arteritis and Polymyalgia Rheumatica. <i>Arthritis and Rheumatology</i> , 2014, 66, 1927-1938.	2.9	104
3	Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis. <i>Medicine (United States)</i> , 2015, 94, e1542.	0.4	93
4	Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. <i>Rheumatology</i> , 2015, 54, 1397-1402.	0.9	83
5	Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 393-399.	0.5	77
6	Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis. <i>JAMA Internal Medicine</i> , 2020, 180, 1295.	2.6	76
7	Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3886-3902.	3.3	55
8	Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?. <i>Arthritis and Rheumatology</i> , 2018, 70, 1366-1376.	2.9	54
9	Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1876-1889.	3.3	51
10	Involvement of Monocyte Subsets in the Immunopathology of Giant Cell Arteritis. <i>Scientific Reports</i> , 2017, 7, 6553.	1.6	45
11	Low-affinity TCR engagement drives IL-2-dependent post-thymic maintenance of naive CD4+ T cells in aged humans. <i>Aging Cell</i> , 2015, 14, 744-753.	3.0	43
12	Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. <i>Rheumatology</i> , 2019, 58, 1383-1392.	0.9	43
13	Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica. <i>Frontiers in Immunology</i> , 2019, 10, 1981.	2.2	40
14	Circulating CD4+CD161+ T Lymphocytes Are Increased in Seropositive Arthralgia Patients but Decreased in Patients with Newly Diagnosed Rheumatoid Arthritis. <i>PLoS ONE</i> , 2013, 8, e79370.	1.1	39
15	Quantifying Distribution of Flow Cytometric TCR-V β 2 Usage with Economic Statistics. <i>PLoS ONE</i> , 2015, 10, e0125373.	1.1	39
16	Distinct macrophage phenotypes skewed by local granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis. <i>Clinical and Translational Immunology</i> , 2020, 9, e1164.	1.7	39
17	SF Treg cells transcribing high levels of Bcl-2 and microRNA-21 demonstrate limited apoptosis in RA. <i>Rheumatology</i> , 2015, 54, 950-958.	0.9	29
18	Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica. <i>Rheumatology</i> , 2022, 61, 1072-1082.	0.9	29

#	ARTICLE	IF	CITATIONS
19	A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL40/Interleukin-13 Receptor \pm 2 Axis. <i>Arthritis and Rheumatology</i> , 2021, 73, 2327-2337.	2.9	27
20	Impact of Aging on the Frequency, Phenotype, and Function of CD161-Expressing T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 752.	2.2	24
21	Towards precision medicine in ANCA-associated vasculitis. <i>Rheumatology</i> , 2018, 57, 1332-1339.	0.9	23
22	Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA. <i>Frontiers in Immunology</i> , 2019, 10, 1638.	2.2	23
23	Age-Associated Differences in MiRNA Signatures Are Restricted to CD45RO Negative T Cells and Are Associated with Changes in the Cellular Composition, Activation and Cellular Ageing. <i>PLoS ONE</i> , 2015, 10, e0137556.	1.1	23
24	Aging-dependent decline of IL-10 producing B cells coincides with production of antinuclear antibodies but not rheumatoid factors. <i>Experimental Gerontology</i> , 2016, 75, 24-29.	1.2	22
25	Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2021, 48, 1053-1059.	1.0	22
26	Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in giant cell arteritis and polymyalgia rheumatica. <i>Journal of Autoimmunity</i> , 2021, 123, 102684.	3.0	20
27	Reduced levels of cytosolic DNA sensor AIM2 are associated with impaired cytokine responses in healthy elderly. <i>Experimental Gerontology</i> , 2016, 78, 39-46.	1.2	18
28	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. <i>Lancet Rheumatology</i> , The, 2021, 3, e71-e82.	2.2	18
29	Changes in peripheral immune cell numbers and functions in octogenarian walkers – an acute exercise study. <i>Immunity and Ageing</i> , 2017, 14, 5.	1.8	15
30	Role of the halo sign in the assessment of giant cell arteritis: a systematic review and meta-analysis. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab059.	0.3	15
31	CD27-CD38 ^{low} CD21 ^{low} B-Cells Are Increased in Axial Spondyloarthritis. <i>Frontiers in Immunology</i> , 2021, 12, 686273.	2.2	15
32	Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. <i>Rheumatology</i> , 2021, 60, 4361-4366.	0.9	15
33	Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage. <i>Lancet Rheumatology</i> , The, 2021, 3, e886-e895.	2.2	15
34	Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment. <i>Journal of Clinical Medicine</i> , 2021, 10, 4958.	1.0	15
35	High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica. <i>Rheumatology</i> , 2020, 59, 176-184.	0.9	13
36	Halo score (temporal artery, its branches and axillary artery) as a diagnostic, prognostic and disease monitoring tool for Giant Cell Arteritis (GCA). <i>BMC Rheumatology</i> , 2020, 4, 35.	0.6	13

#	ARTICLE	IF	CITATIONS
37	Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e210-e210.	0.5	13
38	Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	13
39	Semi-Quantitative and Quantitative [18F]FDG-PET/CT Indices for Diagnosing Large Vessel Vasculitis: A Critical Review. <i>Diagnostics</i> , 2021, 11, 2355.	1.3	12
40	High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins. <i>Arthritis Research and Therapy</i> , 2015, 17, 158.	1.6	10
41	Management of immune checkpoint inhibitor-induced polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e263-e263.	0.5	10
42	Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis. <i>Frontiers in Immunology</i> , 2017, 8, 1377.	2.2	8
43	Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 925-933.	2.0	8
44	Methotrexate in Giant Cell Arteritis Deserves a Second Chance – A High-dose Methotrexate Trial Is Needed. <i>Journal of Rheumatology</i> , 2019, 46, 453-454.	1.0	8
45	Angiotensin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica. <i>Arthritis Research and Therapy</i> , 2022, 24, 65.	1.6	8
46	Phenotypic, transcriptomic and functional profiling reveal reduced activation thresholds of CD8+ T cells in giant cell arteritis. <i>Rheumatology</i> , 2022, 62, 417-427.	0.9	8
47	CD8+ T Cells in GCA and GPA: Bystanders or Active Contributors?. <i>Frontiers in Immunology</i> , 2021, 12, 654109.	2.2	6
48	Therapy response evaluation in large-vessel vasculitis: a new role for [18F]FDG-PET/CT?. <i>Rheumatology</i> , 2021, 60, 3494-3495.	0.9	6
49	Need and value of targeted immunosuppressive therapy in giant cell arteritis. <i>RMD Open</i> , 2022, 8, e001652.	1.8	6
50	Toward Reliable Uptake Metrics in Large Vessel Vasculitis Studies. <i>Diagnostics</i> , 2021, 11, 1986.	1.3	5
51	Response to: “Halo Score™: missing large vessel giant cell arteritis” do we need a modified “Halo Score™” by Chattopadhyay and Ghosh. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e119-e119.	0.5	4
52	The impact of exercise on the variation of serum free light chains. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, e239-42.	1.4	3
53	Response to: “Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care” by Molina Collada et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e176-e176.	0.5	3
54	Response to: “Correspondence on “Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia” by Evangelatos et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e43-e43.	0.5	3

#	ARTICLE	IF	CITATIONS
55	Purulent lupus panniculitis unmasked by FDG-PET/CT scan. <i>Medicine (United States)</i> , 2016, 95, e5478.	0.4	2
56	Response to: "Diagnostic accuracy of novel ultrasonographic halo score for giant cell arteritis: methodological issues"™ by Ghajari and Sabour. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e106-e106.	0.5	2
57	Dr. Conway et al reply. <i>Journal of Rheumatology</i> , 2021, , jrheum.210913.	1.0	2
58	Encouraging data on rituximab in polymyalgia rheumatica. <i>Lancet Rheumatology</i> , The, 2021, , .	2.2	1
59	IMMUNOSENESCENCE AND ITS IMPACT ON MEDICAL PRACTICE. A NEW LOOK AT AN OLD PROBLEM.. <i>Revista Médica Da UFPR</i> , 2014, 1, 156.	0.0	0
60	303. "LEUKOCYTE DYNAMICS BEFORE, DURING AND AFTER TREATMENT IN GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATIC PATIENTS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
61	055. "HIGH SERUM ANGIOPOIETIN-2 LEVELS IDENTIFY LARGE VESSEL INFLAMMATION IN PATIENTS WITH POLYMYALGIA RHEUMATICA. <i>Rheumatology</i> , 2019, 58, .	0.9	0
62	FRI0275 "HIGH ANGIOPOIETIN-2 LEVELS ASSOCIATE WITH ARTERIAL INFLAMMATION AND LONG-TERM GLUCOCORTICOID REQUIREMENT IN POLYMYALGIA RHEUMATICA. , 2019, , .		0
63	SAT0228 "LEUKOCYTE DYNAMICS IN GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA PATIENTS BEFORE, DURING AND AFTER TREATMENT. , 2019, , .		0
64	Mechanisms of Naive CD4+ T Cell Maintenance in the Elderly and Its Implications for Autoimmunity. , 2018, , 1-23.		0
65	Mechanisms of Naive CD4+ T Cell Maintenance in the Elderly and Its Implications for Autoimmunity. , 2019, , 1573-1595.		0
66	PET imaging in vasculitis. , 2021, , .		0
67	Dr. Conway et al reply. <i>Journal of Rheumatology</i> , 2022, 49, 120.2-121.	1.0	0